NCT02873650View on ClinicalTrials.gov

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

October 12, 2018

Study Completion Date

April 8, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

dabrafenib

Single dose of 100 mg dabrafenib on Day 1

Trial Locations (4)

27612

Wake Research Associates Oncology, Raleigh

32713

Omega Research Consultants LLC, DeBary

900017

American Institute of Research, Los Angeles

08009

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY